SeenewsSeenews
Search
Seenews
AlertsSeenewsSeenews
Searchclose
TOPICS
arrow
COUNTRIES
arrow
INDUSTRY
arrow
Economy
arrow
Browse Economy
Mix and match your focus countries with our advanced search
Investments
arrow
Browse Investments
Mix and match your focus countries with our advanced search
Deals
arrow
Browse Deals
Mix and match your focus countries with our advanced search
Tech
arrow
Browse Tech
Mix and match your focus countries with our advanced search
Green
arrow
Browse Green
Mix and match your focus countries with our advanced search
0/5
You have 5 free articles left this month
You have 0/5 free articles
Sign up to get 5 more free articles this month
SIGN UP
arrow
LOGIN
arrow

Bulgaria's Sopharma buys 300 shares in Sopharma Trading

Dec 23, 2020, 12:00:00 AMArticle by Aleksia Petrova
share
SOFIA (Bulgaria), December 23 (SeeNews) - Bulgaria's Sopharma Trading [BUL:SO5] said on Wednesday that its parent, local drug maker Sopharma [BUL:3JR], acquired 300 shares in the company on December 22.

Bulgaria's Sopharma buys 300 shares in Sopharma Trading
Author: Sopharma Trading / All rights reserved.

Sopharma acquired the shares at a price of 5.60 levs ($3.50/2.86 euro) apiece on the Bulgarian Stock Exchange's regulated market, Sopharma Trading said in a bourse filing.

Since the start of December, Sopharma has acquired 24,203 shares in Sopharma Trading.

Also on Wednesday, Sopharma Trading said that the chairman of its board of directors - Ognyan Donev, sold 520 shares in the company at a weighted average price per share of 5.61 levs. Donev sold the Sopharma Trading's shares on the floor of the Bulgarian Stock Exchange on December 22.

Donev is also the CEO and indirectly the biggest shareholder of Sopharma.

Sopharma held a 76.09% stake in Sopharma Trading at the end of September.

As at 15:55 CET on Wednesday, shares in Sopharma traded 1.25% lower at 3.16 levs. Sopharma Trading's shares traded 4.27% lower at 5.60 levs.

(1 euro = 1.95583 levs)

Your complete guide to the emerging economies of Southeast Europe. From latest news to bespoke research – the big picture at the tip of your fingers.